Peptidomimetic‐based identification of FDA approved compounds inhibiting IRE1 activity
Inositol-requiring enzyme 1 (IRE1) is a bifunctional serine/threonine kinase and endoribonuclease that is a major mediator of the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress. Tumour cells experience ER stress due to adverse environmental cues such as hypoxia or nutrient...
Main Authors: | Doultsinos, D, Carlesso, A, Chintha, C, Paton, JC, Paton, AW, Samali, A, Chevet, E, Eriksson, LA |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2020
|
Similar Items
-
Pharmacological targeting of IRE1 in cancer
by: Pelizzari Raymundo, D, et al.
Published: (2020) -
A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment
by: Diana Pelizzari-Raymundo, et al.
Published: (2023-05-01) -
Sensor dimer disruption as a new mode of action to block the IRE1-mediated unfolded protein response
by: Kosala N. Amarasinghe, et al.
Published: (2022-01-01) -
Binding Analysis of the Inositol-Requiring Enzyme 1 Kinase Domain
by: Antonio Carlesso, et al.
Published: (2018-10-01) -
FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)